About FAST

Welcome!

FAST was founded in 2008 with an urgent mission: to cure Angelman syndrome. Today, with operations in the United States, Australia, the UK, Canada, Italy, France, Spain and Latin America, our organization is the largest non-governmental funder of Angelman syndrome research, and we take this responsibility seriously. All financial gifts are invested wisely, and 94.3% of every dollar goes to support critical research! And, we don’t just write checks. FAST has set the research agenda for Angelman syndrome from bringing together a multidisciplinary team of more than two-dozen scientists from top research universities and pharmaceutical companies to join forces on a focused path to a cure to ensuring potential therapeutics do not languish in the laboratory. FAST formed the subsidiary, GeneTx Biotherapeutics, in order to develop an antisense oligonucleotide as a potential treatment for Angelman syndrome. FAST and GeneTx advanced this program from a proof of concept in the laboratory into clinical development. FAST was the first rare-disease patient organization to take this approach. GeneTx was the very first company to trial a potentially disease-modifying drug in this patient population.

Whereas most rare disease patient organizations would begin to relax and wait (and pray) for the results of their decisions, strategies and hard work to pay off, FAST is poised to work harder than ever to create meaningful change for the Angelman community. All of the advancements in Angelman syndrome, as well as FAST’s mission, would not be possible without the continued support of our community. All of us at FAST remain enormously grateful for your support and look forward to the many advancements that lie ahead as we #cureangelman.

Now is the time for action. FAST’s Roadmap to a Cure is bold, ambitious, and, with your help, achievable. Please join us by making a financial gift, spreading the word with friends and family members, and fundraising to help us cross the finish line. Our ultimate goal is to successfully complete this race – and no longer be necessary – by finding a cure.

The FAST Board
PO Box 608
Downers Grove, IL 60515

Phone: (630) 852-FAST
Fax: (630) 852-3270
Toll Free: (866) 783-0078
Email: info@cureangelman.org

  • Our Role & Mission
  • Our Priorities
  • Funding Philosophy
  • Transparency

FAST is run by an all-volunteer board of Angelman syndrome (AS) parents and professionals dedicated to finding a cure for AS and related disorders through the funding of an aggressive research agenda. The foundation is committed to assisting individuals living with Angelman syndrome to realize their full potential and quality of life. Our goal is to bring practical treatment into current medical practice as quickly as possible. It is our hope that grants we fund will lead to additional research support from government agencies, other funding sources and organizations around the globe. FAST is served by two boards: the board of directors and the scientific advisory board. Together, we are working hard to bring practical treatment into current medical practice as quickly as possible.

We are 100 percent committed to accelerating treatments and a cure for Angelman syndrome (AS). The symptoms of AS have been under-addressed in the research community for far too long. Research aimed at identifying treatments for the motor dysfunction, seizures and behavioral characteristics of Angelman syndrome is one of FAST’s top priorities. FAST takes pride in investing in high-risk, high-reward research grants that have already produced positive and promising results. A cure for AS is now within reach but will require the expertise and collaboration of the best and brightest minds from a variety of fields in science and research.

In 2013, a true research collaboration and the infrastructure required to advance a cure for Angelman syndrome, was nonexistent. FAST addressed this challenge by creating the first-of-its-kind FIRE Initiative (FAST Integrative Research Environment), which funds more than two-dozen scientists from top universities to work collaboratively to identify, characterize and implement new therapeutics for the treatment and ultimate cure for Angelman syndrome. The FIRE Initiative is the most aggressive research program to date dedicated to finding a cure for AS.

For decades, small, non-profit disease research organizations like FAST have modeled their funding philosophies after the National Institutes of Health (NIH) where they budget their research dollars, put out a once-a-year call for applications, wait for scientists to come to them with ideas, select the most promising applications and hope they actually see results.  FAST is not at all interested in this slow, linear approach to funding research and instead adopted the innovative model of venture philanthropy, recruiting a stellar in-house team to work in partnership with leading scientists on ambitious, high-risk/high-reward study designs that will ensure promising therapeutics make it from the laboratory bench to the patient’s bedside as quickly as possible.

Adopting a business model where we have input and control over the direction of the research, FAST assembled an in-house team of experts in science, medicine, business management, finance, law, accounting and technology.  In addition to funding research grants, including over $360,000.00 in Postdoctoral Fellowships, FAST has also entered into contracted research on targeted projects with well defined milestones and deliverables.

Angelman Syndrome is currently one of the most promising fields of scientific research; relying solely on investigator-initiated research to identify and implement patient treatments is inefficient and short sighted.  Additionally, true collaboration of researchers working cooperatively is the only successful approach to treatment science.

In January 2011, FAST contracted research with Dr. Edwin Weeber to test four FDA approved compounds in our mouse model.  One of those compounds, Minocycline, showed promise in treating some of the symptoms of AS.  With additional funding and testing, Minocycline was identified as a candidate for human clinical trial.  FAST provided the funding for the trial in 2012 and we anticipate results to be published soon.

In May of 2013, FAST launched the most aggressive Angelman research initiative in history, bringing 24 researchers from 4 universities together in true collaboration to identify additional treatments and a cure for Angelman Syndrome.  The FAST Integrative Research Environment (FIRE) Initiative has already identified several possible treatment candidates for human clinical trial.  FAST will continue to either fund small, proof of concept trials that will better position the Angelman community for larger FDA funding and/or partner with pharmaceutical companies to bridge the so-called “Valley of Death” in translational research.

FAST has proven the success of our funding philosophy in a very short amount of time and with relatively little funding. It is not about how much you spend, but rather how you spend it.  FAST is funding smarter, faster science and with proper funding, a cure is now just within our reach.

FAST (Foundation for Angelman Syndrome Therapeutics) is an Internal Revenue Code Section 501(c)(3) nonprofit charity, exempt from federal taxation. Transparency is both a requirement and an obligation that is also vitally important to our members. 

FAST (Foundation for Angelman Syndrome Therapeutics) is an Internal Revenue Code Section 501(c)(3), a nonprofit charity, exempt from federal taxation. Transparency is both a requirement and an obligation that is also vitally important to our members.

View FAST’s W9 form.

"When the FAST community comes together with the brightest minds in the scientific field, positive, transformational change is happening."
Paula Evans
CEO of GeneTx Biotherapeutics
"Put the concept that “age matters” behind you and let human trials prove that ALL humans living with AS may very well benefit from gene replacement or gene altering therapies, regardless of age."
Dr. Allyson Berent
FAST Chief Science Officer
“Of all the childhood genetic neurologic disorders of the brain, Angelman syndrome may be the single best candidate for developing a definitive treatment (aka a cure).”
Dr. Arthur Beaudet
Professor
"It was the science that bought me into this, but it was the community that made me want to stay"
Dr. David Segal
Professor
“Research in Angelman syndrome offers the opportunity to unlock the ingenuity that we see every day interacting with individuals with AS. They can figure out any device and are avid problem solvers. We want to hear what they have to say. Their joy pushes us forward to figure out how we can improve their lives on a daily basis.”
Dr. Jessica Duis
Children Hospital Colorado
“FAST was such an integral part of my academic life. This outstanding foundation supported my work on Angelman syndrome for so many years. I am deeply humbled by this honor and by this opportunity to meaningfully contribute to FAST’s mission to cure Angelman syndrome.”
Dr. Jimmy El Hokayem
Biorasi, LLC

Leadership & Staff

FAST is served by two boards who work together to bring practical treatments into current medical practice as quickly as possible.

  • Board of Directors
  • Staff
  • Scientific Advisory Board
  • FAST Advisory Council
Allyson Berent.2 1

John Schlueter

Position: Chairperson

John is the owner of Frontline Commercial Real Estate, LLC, where he develops, acquires, finances, and leases retail and industrial commercial real estate. Concurrently, his manufacturing business, Keder Solutions LLC, designs, manufactures, and distributes textile reinforcement products internationally. Prior to this, John led his family business to become the largest manufacturer and installer of temporary structures. A few notable clients include Walt Disney World, NFL/Super Bowl, IMG/New York Fashion Week, and the 2010 Vancouver Winter Olympic Games. John’s daughter Grace has Angelman syndrome.

John Schlueter

Chairperson
Allyson Berent.2

Allyson Berent‑Weisse

Position: Chief Science Officer

Allyson is a veterinarian in New York City. She received a bachelor’s degree and doctor of veterinary medicine degree from Cornell University. She is a member of the American College of Veterinary Internal Medicine and is a specialist in internal medicine and interventional radiology/interventional endoscopy. She is a director of interventional endoscopy at one of the largest specialty animal hospitals in the world. She has spent the last 10 years performing clinical research and designing various clinical trials to develop and evaluate novel therapeutics and medical devices in dogs and cats. Allyson has three children. Her daughter Quincy has Angelman syndrome.

Allyson Berent‑Weisse

Chief Science Officer
Kelly David

Kelly David

Position: Vice Chair

Kelly received a Bachelor of Science degree in biology and Master of Arts degree in communication sciences and disorders from the University of Central Florida. She is a member of the American Speech-Language Hearing Association (ASHA) and holds a license to practice speech-language pathology in the state of Florida. She works at a local hospital as an acute care speech-language pathologist and at the University of Central Florida as an adjunct clinical educator. Kelly’s career is focused on the evaluation and treatment of dysphagia and cognitive/communication disorders resulting from acquired brain injuries in adults. She has conducted research and presented at the national level. Kelly lives in Orlando, Fla., with her husband, Brian, and their son, Colin, who has Angelman syndrome.

Kelly David

Vice Chair
ben oconnor 1 1

Ben O’Connor

Position: Treasurer

Ben O’Connor, director, is a litigation and trial attorney for Hilliard Martinez Gonzales LLP in Chicago, where he focuses on personal injury and mass tort cases. He previously worked for Kirkland & Ellis LLP in Chicago, with broad practices in commercial litigation, white-collar criminal defense, criminal postconviction relief, and government and internal investigations. He received his bachelor’s degree from the University of Notre Dame, a master’s degree from Saint Louis University, and a Juris Doctor from The John Marshall Law School in Chicago. Prior to joining Kirkland & Ellis, Ben served as a law clerk for the Hon. William J. Bauer on the United States Court of Appeals for the Seventh Circuit in Chicago. Before becoming an attorney, Ben was a high school theology teacher and football coach at Loyola Academy in Wilmette, Illinois. Ben lives outside of Chicago with his wife, Elizabeth, and their two children. His son, Ryan, has Angelman Syndrome.

Ben O’Connor

Treasurer
Roy Azout

Roy Azout

Position: Director

Roy received a Bachelor of Science degree in economics from The Wharton School at University of Pennsylvania, where he graduated magna cum laude. He is owner and corporate manager at Lafayette S.A.S., a vertically integrated, state-of-the-art, textile manufacturing and distribution company, which was founded in 1942 and has customers in 24 countries around the world. Roy grew up and lives in Bogota, Colombia. Roy has three children, his daughter Michelle has Angelman syndrome.

Roy Azout

Director
Amelia Beatty 1

Amelia Beatty

Position: Director

Amelia Beatty received her undergraduate degree from Wellesley College and her Master of Arts degree at Sotheby’s Institute of Art London. Amelia has lived and worked in San Francisco, Boston, London, Los Angeles, Shanghai, China; Brazzaville, Congo and Algiers, Algeria. Her diverse jobs have included catering, managing an art gallery, managing security for diplomats, and working with the U.S. Department of Defense. Amelia and her husband have three sons. Their middle son has a congenital heart defect and apraxia of speech. Their youngest son, Orion, has Angelman syndrome. Becoming fluent in French while living abroad, Amelia and her husband decided to have a bilingual family, and have largely succeeded in spite of the communication challenges with two of their children. Amelia and her family live in Amman, Jordan.

Amelia Beatty

Director
Meagan Cross

Meagan Cross

Position: Director

Meagan has a background in information science operates a geographic information science consultancy with experience in data development, management, analysis and presentation. Meagan also runs a business in Far North Queensland Australia with her husband, Rohan. In addition, Meagan is chairperson of sister organization FAST-Australia and the founder of the Global Angelman Syndrome Registry. Meagan has two children. Her daughter Molly has Angelman syndrome.

Meagan Cross

Director
K Dixon profile pic

Kristy Dixon

Position: Secretary

Kristy is an international program manager for Lockheed Martin in Orlando, Fla. Kristy has worked at Lockheed Martin since 2002 in various customer-facing positions within engineering, business development and program management. Her strengths in building personal customer relationships, developing and executing win strategies, and leading cross-functional teams has enabled her to find solutions that meet customer needs resulting in the award of significant customer funds. Kristy earned a Bachelor of Science degree in computer and information sciences from the University of Florida and a Master of Science degree in computer science from the Florida Institute of Technology. Kristy has a daughter, Grace, with Angelman syndrome.

Kristy Dixon

Secretary
Lauren Hoffer

Lauren Hoffer

Position: Director

Lauren is an attorney for Dell Technologies. Lauren handles high stakes intellectual property litigation, licensing, and various legal matters for the company. Prior to joining Dell, Lauren practiced law at Morgan Lewis & Bockius and Jones Day law firms where she focused on commercial and IP litigation. Lauren earned her undergraduate degree from the University of Texas at Austin and her law degree from Georgetown University Law Center. Throughout her life, Lauren has been an active community leader and volunteer, serving on boards and committees for various civic and charitable organizations. Lauren lives in Austin, Texas with her husband Greg and their two sons, Charlie and Ben, who has Angelman Syndrome.

Lauren Hoffer

Director
RJ1

Ryan Jacob

Position: Director

Ryan is the chief executive officer for CAE, a global software- and information-driven trading firm addressing the semiconductor market. Additionally, Ryan is a chairman of Jacob Family Holdings and serves as a director for numerous private companies. Prior to CAE, Ryan worked in venture capital and private equity at Summit Partners, Endeavour Capital and Celerity Partners. He’s a graduate of the University of California, Los Angeles. Throughout his career, Ryan has been focused on investing in and helping to grow private companies and conveying those beneficial practices to non-profit organizations. Ryan’s son Grayson has Angelman syndrome.

Ryan Jacob

Director
nora

Nora Xu

Position: Director

Nora is the Group Marketing Manager for Microsoft. In her role at Microsoft, Nora leads a team focused on integrated marketing programs and initiatives to establish a unified message for Microsoft Advertising. Nora has over 10 years of combined experience at Microsoft. Prior to her current role at Microsoft, Nora worked as a product marketing manager for well-known mobile and web application brands. She is a graduate of the University of Waterloo in Canada. Nora brings 20 years of extensive marketing experience with a background in creative marketing, storytelling, strategic partnerships and community engagement to the FAST Board of Directors. Nora’s daughter, Arbor, has Angelman syndrome.

Nora Xu

Director
paula2

Paula M. Evans

Position: Founder

Paula earned a Bachelor of Science degree in architectural technology from the New York Institute of Technology. Her career focused on residential and commercial property management in both Manhattan and Chicago. Paula oversaw the management and title transfer of multimillion-dollar properties, and handled all property negotiations, purchasing, construction/renovation projects and staff supervision. Her portfolio contained some of the highest-profile buildings and entities in the above-mentioned cities. Paula has two children. Her daughter, Ainsley, has Angelman syndrome.

Paula M. Evans

Founder
maiddy dunigan 2

Maiddy Dunigan

Position: Chief Operating Officer

Maiddy received a Bachelor of Arts degree in communications from University of Nevada, Reno; a Juris Doctor degree from California Western School of Law, cum laude; and a Master of Laws degree from Georgetown Law Center, with honors. She is a member of the American Bar Association and a member of the State Bar of California. Maiddy is licensed to practice in front of the Supreme Court of the United States. Maiddy spent more than 10 years at KPMG LLP and Ernst & Young LLP as a federal tax services manager in international practices. She specialized in mergers and acquisitions. Maiddy provided tax services to multinational companies in numerous domestic and international situations. Maiddy has four children. Her son Jaxson has Angelman syndrome.

Maiddy Dunigan

Chief Operating Officer
Kena head shot 2019

Kena Richert

Position: Chief Financial Officer

Kena is a certified public accountant with The Church at Horseshoe Bay. Prior to assuming a local accounting role to spend more time with her family, she worked at Pricewaterhouse Coopers LLP in the Assurance Practice. She provides audit services to a Fortune 50 technology company as well as other smaller private companies in various industries. She received a Bachelor of Business Administration degree in accounting from Southwest Texas State University and graduated magna cum laude. Kena is a member of the American Institute of Certified Public Accountants, Texas State Board of Public Accountancy, and the National Association of Church Business Administration. Kena has three children. Her daughter Ashley has Angelman syndrome.

Kena Richert

Chief Financial Officer
IMG 4237001

Alice Shannon

Position: Director of Operations

Alice earned a Bachelor of Science degree in business administration from the State University of New York, Empire State College. Her career focused on accounting in both Manhattan and Chicago. Alice spent most of her career in Manhattan working for Morgan Stanley in the Controllers department. She currently lives in Chicago and has a niece with Angelman Syndrome.

Alice Shannon

Director of Operations
Alberini

Christina Alberini
Ph.D., L.P.

Position: Professor

The Center for Neural Science
New York University
View Website
Specialty: memory and learning

Christina Alberini
Ph.D., L.P.

Professor
Anne Anderson

Anne Anderson
M.D.

Position: Associate Professor

Departments of Pediatrics and Neurology and Division of Neuroscience Baylor College of Medicine Houston, TX
Visit Website
Specialties: Clinical Neurophysiology, Pediatric Neurology

Anne Anderson
M.D.

Associate Professor
Joe Anderson

Joseph Anderson
Ph.D.

Position: Associate Professor

Associate Professor with the Gene Therapy Center at UC Davis.
View Website
Specialty:  Infectious Diseases, Internal Medicine

Joseph Anderson
Ph.D.

Associate Professor
barbara bailus

Barbara Bailus Ph.D.

Position: Scientific Advisory Board Chair

Assistant Professor of Genetics
Institution: Keck Graduate Institute, Claremont Colleges

Website: https://www.kgi.edu/people/barbara-bailus/

Specialty: Genetic Engineering, Protein Delivery

Dr. Barbara Bailus is an Assistant Professor of Genetics at The Keck Graduate Institute, of the Claremont Colleges. She did her doctoral research at University of California, Davis in the Segal Laboratory developing a gene therapy based on artificial transcription factors for the treatment of Angelman Syndrome.  Her postdoctoral research in the Ellerby Lab at The Buck Institute for Research on Aging, focused on potential therapies for Huntington’s disease including small molecules and gene editing proteins.  For the past several years Dr. Bailus has been honored to serve as a scientific advisor and communications reporter for The Foundation for Angelman Syndrome Therapeutics (FAST).  Dr. Bailus has a passion for teaching the next generation of scientists and communicating exciting scientific advances to the public.  When not in the lab or classroom she enjoys being outside, traveling, riding horses, and painting.

Barbara Bailus Ph.D.

Scientific Advisory Board Chair
portrait bartolomei

Marisa S. Bartolomei
Ph.D.

Position: Professor Department of Cell and Developmental Biology
Perelman Professor of Cell and Developmental Biology
Professor of Genetics, University of Pennsylvania School of Medicine
Director of IRM Program in Reproductive Medicine, University of Pennsylvania
Co-Director Epigenetics Program, University of Pennsylvania Perelman School of Medicine
Department: Cell and Developmental Biology
Visit Website
Specialties: genomic imprinting, X inactivation, DNA methylation, epigenetics

Marisa S. Bartolomei
Ph.D.

Professor Department of Cell and Developmental Biology
Art Beaudet

Art Beaudet
M.D.

Position: Founder and CEO of Luna Genetics

Texas Children’s Hospital
View Website
Specialty: Genetics

Art Beaudet
M.D.

Founder and CEO of Luna Genetics
lauren black

Lauren E. Black
Ph.D

Position: Distinguished Scientist

Charles River Laboratories
Specialty: preclinical assessment of transplant drugs, oligos, monoclonals for autoimmune disease, treatment vaccines, and cell therapies

Lauren E. Black
Ph.D

Distinguished Scientist
Carson Robert

Robert Carson
Ph.D.

Position: Professor
Specialty:
  • Epilepsy
  • Pediatric Neurology
Vanderbilt Children’s Hospital 

Robert Carson
Ph.D.

Professor
Jessica Duis

Jessica Duis
M.D., M.S.

Position: Assistant Professor of Pediatrics

Assistant professor University of Colorado.
Children’s hospital of CO.
Clinical genetics and genomics general pediatrics
View Website
Specialty: Medical Genetics

Jessica Duis
M.D., M.S.

Assistant Professor of Pediatrics
13a.Jimmy El Hokayem

Jimmy El Hokayem Ph.D.

Position: Associate Director, Program Development

Head of the Neurology and Regenerative Medicine Centers of Excellence at Biorasi and Associate Director of Program Development.

As head of Biorasi’s Neurology and Regenerative Medicine Centers of Excellence, Dr. El Hokayem oversees all clinical studies and projects related to neurological indications, cell and gene therapies. He leverages his unique expertise in the basic, translational, and clinical research spectrum and provides critical insights at strategic, operational, and managerial levels. Dr. El Hokayem is an expert clinical trial decentralizer and an early adopter of digital technologies in clinical studies as well as digital therapeutics.

Dr. El Hokayem received his Ph.D. from University of Miami, Miller School of Medicine, in Biochemistry and Molecular Biology. He continued his training with post-doctoral work at the University’s Hussman Institute for Human Genomics.

With over twenty years in both academia and the clinical research industry, Dr. El Hokayem has focused his research on rare neurological diseases; namely in Angelman Syndrome (AS), where he was the first to demonstrate the long overlooked role of the transcriptional coactivation function of UBE3a in the pathobiology of AS, and opened new avenues for biomarker development. Furthermore, Dr. El Hokayem published over twenty peer reviewed papers and received multiple awards from international foundations and entities.”

Jimmy El Hokayem Ph.D.

Associate Director, Program Development

2019 Terry Jo headshot orange

Terry Jo V. Bichell Ph.D.

Position: Council Member

Dr. Terry Jo V. Bichell has a Ph.D. in Neuroscience. She is the founder and director of COMBINEDBrain, which is devoted to speeding the path to clinical treatments for people with severe rare genetic non-verbal neurodevelopmental disorders. While working as a documentary filmmaker, Dr. Bichell’s youngest child, Lou, was diagnosed with Angelman syndrome. She quickly switched focus to help move bench science into the first clinical trials for Angelman syndrome. Dr. Bichell is a highly-published, experienced researcher with a history of working in neuroscience and women’s health.

Terry Jo V. Bichell Ph.D.

Council Member
Dr. Joe D Orazio

Joe D’Orazio Ph.D.

Position: Council Member

Assistant Professor of Emergency Medicine
Institution: Lewis Katz School of Medicine at Temple University

Dr. D’Orazio serves as a medical toxicology consultant for the Poison Control Center at the Children’s Hospital of Philadelphia. He brings extensive experience in emergency medicine, medical toxicology, addiction medicine and has been involved in various clinical trials. His son, Gabriel, has Angelman syndrome.

Joe D’Orazio Ph.D.

Council Member
Jim Daley cropped sml

Jim Daley Ph.D.

Position: Council Member

Research Assistant Professor
Institution: University of Texas Health Science Center, San Antonio

Dr. Jim Daley attended the University of Michigan for his Ph.D. in Cellular and Molecular Biology, and performed postdoctoral work at the University of Montreal and Yale University. He studies DNA damage, genome instability and cancer. Dr. Daley has a younger sister, Jennie, with Angelman syndrome.

Jim Daley Ph.D.

Council Member
Derek Matheson

Derek Matheson Ph.D.

Position: Council Member

Director of hospitalists
Institution: Jane Phillips Medical Center

Dr. Derek Matheson is a graduate of Oklahoma State University College of Osteopathic Medicine and has over two decades of internal medicine experience. Dr. Matheson’s youngest child, Remi, was diagnosed with Angelman syndrome in June 2018.

Derek Matheson Ph.D.

Council Member

Colin Farrell on FAST​

Colin Farrell speaks about Angelman syndrome, the Foundation for Angelman Syndrome Therapeutics and the FAST Gala.

video thumbnails colin
Play Video

FAST is Global

In an age where Angelman syndrome therapeutics are being developed on a global scale, FAST is working to make sure communities across the world are organized and prepared to participate in studies for potential therapeutics. FAST is committed to bringing the Angelman syndrome community the most current updates on research and clinical trials. Hear from each country’s FAST chairperson in this video and learn more about how they are all advancing Angelman syndrome research and clinical trials. 

global
Play Video

FAST has affiliates in Argentina, Australia, Canada, Colombia, France, Italy, Spain, and the UK.

australia3
canada3
france3
italy3
FASTSpain2
uk3
LatAm

A FAST History

1997
August 2008
December 2008
October 2010
September 2011
December 2011
April 16, 2012
December 2012
December 2, 2012
June 2013
February 15, 2014
April 2015
July 2015
November 2015
March 7, 2016
July 2016
September 2016
October 2016
February 2018
March 2018
July 2018
October 2019
February 2020
May 2020
May 2020
May 2020
August 2020
Dr.ArtBeaudet
Dr. Art Beaudet discovers UBE3A is the causative gene for Angelman syndrome.
Picture1
FAST Launches
1st Gala NewsLetter February2009.2
FAST Hosts First Gala
FAST Australia is Launched
FAST
Vivint Gives Back-win $250,000
RKP 101
2011 FAST Gala
526197 10150807243666277 414134024 n
1st FAST funded clinical trial-Minocycline with Dr. Weeber
The FIRE Team
FIRE (FAST Integrative Research Environment) is launched
Screen Shot 2020 11 11 at 5.16.49 PM
1st Annual Scientific Round Table (Science Summit)
CFC 2ApprovedCharity 2C Blue
FAST is included on the Combined Federal Campaign (CFC) Charity List.
1st Annual International Angelman Day
jeremy levin ovid
Ovid Therapeutic Launches first sponsored clinical trial for AS
Ed Weeber Agilis Announcement
Dr. Edwin Weeber and Agilis Biotherapeutics enter into worldwide licensing agreement for Angelman syndrome gene therapy
Agilis Nov 2015
Agilis Biotherapeutics announces FDA orphan drug designation for AGIL-AS for treatment of AS
boimarkers2 scaled
The Angelman Biomarkers and Outcome Measures Consortium is created
stem cells IRC signage700
FAST Funded Research leads to $1.1 million grant
FAST Receives $5.8 million grant from Marnier-Lapostolle Foundation
FASTUK 3 scaled
FAST UK is formed
GeneTx.Logo Transparent high res
FAST announces the launch of GeneTx Biotherapeutics, a subsidiary of FAST
GeneTx Biotherapeutics receives FDA orphan-drug designation for Angelman syndrome treatment
Zev Noah FAST Canada
FAST Canada is formed
FAST Italy with Colin
FAST Italy is formed
GTX102 Clinical Study
GeneTx Announces GTX-102 is approved for clinical study.
Charity Navigator 4StarRect
FAST rated a 4-star charity by Charity Navigator
Segal Lab group outdoor
FAST funds UC Davis team to build a lab devoted to Angelman syndrome (AS) research
Bienvenue FAST France2
Bienvenue FAST France
Partnership with HealX.2
Healx-FAST Collaboration

Resources

can3.1.21
As diverse as our Angelman community is, we are all united in one goal: a better future for our children. FAST is committed to bringing life-changing treatments to all individuals with Angelman syndrome, but we need your help!
can3.1.21
As diverse as our Angelman community is, we are all united in one goal: a better future for our children. FAST is committed to bringing life-changing treatments to all individuals with Angelman syndrome, but we need your help!
X
X